Loading, please wait...
RESIDENT SEMINAR SCHEDULE
Wednesday, October 28, 2020
St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis
Academic Research Building (ARB) and Virtually
|
|
ARB 337
|
ARB 406
|
ARB 469
|
|
SESSION 1
12:15 pm – 1:00 pm
|
Dan Ilges, Pharm.D.
Treatment of Carbapenem-Resistant Enterobacterales in 2020
|
Lavinia Salama, Pharm.D.
Emerging Therapies for the Treatment of Community-Acquired Pneumonia
|
Makenzie Hollingsworth, Pharm.D.
Treatment of Hereditary Angioedema
|
|
1:00 pm – 1:05 pm
|
Break for Transition between Speakers
|
||
|
SESSION 2
1:05 pm – 1:50 pm
|
Michelle Sproat, Pharm.D.
Introduction to Biosimilars
|
Smita Rausaria, Pharm.D.
Steroids in Septic Shock: Yes, No, or Maybe?
|
Deja Finley, Pharm.D.
The use of Long-Acting Antipsychotics in Patients with Schizophrenia during the Coronavirus Disease-19 Pandemic
|
Please join us for the third Resident Seminar session of the 2020-2021 academic year. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series focuses on current therapeutic topics in the practice of pharmacy. All sessions will be held in the classrooms in the Academic & Research Building (ARB) on the third and fourth floors, as well as virtually.
* Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned is 1.50 contact hours. Participants must complete an evaluation to receive credit.
REGISTRATION & PARKING INFORMATION
Live registrations are submitted by RPDs and through survey monkey only. Due to a limited number of live available classroom spaces, a maximum of 22 people are allowed per classroom. Virtual registrations are limitless and completed through survey monkey. Please note, this event has multiple concurrent sessions.
Registration is free, but is required in advance. Due to limited space, only those participants who register before 5:00 PM on Friday, October 23, 2020 will be able to request parking access on campus.
PARKING: To request parking, please first register for your desired sessions. Then, complete the parking questionnaire using the link above, or complete your parking request by clicking here>>>. If you do not request parking on our campus, or if you do not submit your request by the deadline, you will be re-directed upon arrival.
HANDOUTS: Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following the presentation, registered participants will receive an email with a link to the evaluation. Within one week after attending the session, participants must complete this online evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live presentation. Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following the presentation, registered participants will receive an email with a link to the evaluation. Within one week after attending the session, participants must complete this online evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live presentation. Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
It is recommended that participants log on and review the information under "My Account" prior to completing evaluations. The NABP ePID and date of birth fields must be accurate for credit reporting to occur. Participants are encouraged to check their NABP eProfiles for receipt of credit within two weeks of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact Nicole Fields at Nicole.Fields@uhsp.edu soon as possible. To best comply with ACPE's CE credit reporting policy, the University of Health Sciences and Pharmacy is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
After one week, evaluations will close and CPE credit may no longer be claimed. If the deadline is missed or if a CE credit correction must be issued, an additional fee may be incurred for late submission - please see our policy, located on the FAQ page for details. Evaluations close November 4, 2020 at 11:59 PM (CDT).
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify Nicole Fields via email at Nicole.Fields@uhsp.edu in advance so that she may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Oct 28, 2020 12:00 PM - 02:00 PM
Fee
$0.00
CE Hours
4.50
Activity Type
- Knowledge
Accreditation(s)
|
St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To learn more about the specific program information, including universal activity numbers (UAN's) and learning objectives, please expand the modules below. Following successful completion of an evaluation, CE credit will be automatically reported to NABP through the CPE Monitor system, using the NABP ePID numbers and date of birth (MMDD) stored in participants' user profiles. Follow this link to learn more about CPE Monitor and the credit reporting process » Participants are responsible for ensuring receipt of credit; no credit can be corrected or awarded if more than 60 days have passed from the date of the event or if the home study is expired.
It is the policy of St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in this program are expected to disclose to the program audience any real or apparent conflicts of interest related to the content of the presentation.
|
Carbapenem-resistant Enterobacterales (CRE) pose a significant public health threat in the twenty-first century. These multidrug-resistant organisms (MDROs) have been cited by both the CDC and WHO as critical pathogens necessitating aggressive action in terms of drug development and resistance prevention measures. In recent years, pharmaceutical companies have answered with a host of new antibiotics specifically targeting CRE. These agents, including ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, and cefiderocol, among others, offer new opportunities in the treatment of CRE infections; however, thorough understanding of their unique properties is vital to ensure safe and effective use. This presentation will provide an overview of CRE, discuss mechanisms of CRE resistance, review the efficacy of novel agents demonstrated in clinical trials, and ultimately provide recommendations for treating CRE in the year 2020. By the end of the presentation, audience members should have the skills to confidently select and recommend novel antibiotics to treat CRE.
Objectives
- Summarize the epidemiology of carbapenemases.
- Describe disadvantages of traditional CRE treatment regimens (i.e. colistin-based regimens).
- Select appropriate antimicrobial regimens to treat CRE infections.
Speaker(s)/Author(s)
|
Daniel Ilges, Pharm.D. |
Activity Number
0033-0000-20-041-L01-P
Date:
10/28/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 355 and Virtually
Pneumonia is one of the most common causes of hospitalization and a leading cause of infectious death. Common bacterial pathogens in community-acquired pneumonia (CAP) include Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumonia, Staphylococcus aureus and atypical organisms Legionella species, Chlamydia pneumoniae, and Moraxella catarrhalis. The 2019 IDSA CAP guidelines recommend macrolides, β-lactams and fluoroquinolones as first line agents. Strep pneumonia and S. aureus resistance to macrolides and oral penicillins are rising in the community. High rates of resistance coupled with increasing safety concerns of increase the need for new treatment options. Lefamulin, a pleuromutilin antibiotic, and omadacycline, a tetracycline antibiotic, will be reviewed in the CE activity.
Objectives
- Identify risk factors and emerging trends of resistance in community-acquired bacterial pneumonia (CABP).
- Identify the 2019 ATS/IDSA guideline recommendations for the treatment of CABP.
- Discuss emerging therapies in the treatment of CABP, including mechanisms of action, dosage forms, costs, safety and efficacy data.
- Identify potential place in therapy for the emerging agents for CABP.
Speaker(s)/Author(s)
|
Lavinia Salama, Pharm.D. |
Activity Number
0033-0000-20-057-L01-P
Date:
10/28/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 305 and Virtually
This CE presentation will review the pathophysiology behind hereditary angioedema, explore the pharmacology of the different treatment options for the management of this rare, genetic condition, and evaluate the pertinent literature surrounding the different agents to determine therapy optimization for this patient population.
Speaker(s)/Author(s)
|
Makenzie Hollingsworth, Pharm.D. |
Activity Number
0033-0000-20-054-L01-P
Date:
10/28/20
Time:
12:15 PM - 01:50 PM
CE Hours
0.75
Location
ARB 337 and Virtually
This session I will define and review information on biologics, biosimilars, and interchangeable products. Review how biologics and biosimilars differ form small molecule drugs and their generics. Discuss the approval process for biosimilars as well as the opportunities and challenges they present. At the end of this session my goal is for the audience to have a basic understanding about the fundamentals of biosimilars to help continue to educate themselves and patients as biosimilars continue to come to market.
Speaker(s)/Author(s)
|
Michelle Sproat, Pharm.D. |
Activity Number
0033-0000-20-055-L01-P
Date:
10/28/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Septic shock is a state of sepsis associated with acute circulatory collapse characterized by persistent arterial hypotension.
Initial management of a patient with septic shock is widely accepted and consists of early administration of broad-spectrum antibiotics, crystalloid or colloid fluid resuscitation, and use of vasopressor support to improve hemodynamics. The management of patients with septic shock refractory to fluids and initial vasopressors is less consistent, especially with regard to the administration of corticosteroids. This session will discuss the available literature regarding optimal use of corticosteroids in septic shock and will specifically focus on articles published in the last 5 years and their perceived impact on patient care.
Initial management of a patient with septic shock is widely accepted and consists of early administration of broad-spectrum antibiotics, crystalloid or colloid fluid resuscitation, and use of vasopressor support to improve hemodynamics. The management of patients with septic shock refractory to fluids and initial vasopressors is less consistent, especially with regard to the administration of corticosteroids. This session will discuss the available literature regarding optimal use of corticosteroids in septic shock and will specifically focus on articles published in the last 5 years and their perceived impact on patient care.
Speaker(s)/Author(s)
|
Smita Rausaria, Pharm.D. |
Activity Number
0033-0000-20-056-L01-P
Date:
10/28/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
The Coronavirus Disease 2019 (COVID-19) pandemic has had a large impact on access to care for the mental health population. To date, there has not been any official guidance on how to address adherence issues that have
arisen due to the COVID-19 pandemic and subsequent quarantine. This presentation reviews the implications for the use of long-acting injectable antipsychotics (LAIs) in patients with schizophrenia to manage psychotic symptoms, reduce hospitalizations, and maintain adherence during the COVID-19 pandemic. Topics to be discussed include the general landscape of mental health before and during the COVID-19 pandemic, treatment recommendations for schizophrenia, recommendations for the use of long-acting injectable antipsychotics, and the role of the community pharmacist in treating schizophrenia during the pandemic. The goal of the presentation is to provide guidance on how to evaluate the appropriateness of the use of LAIs and their impact on adherence in patients with schizophrenia.
arisen due to the COVID-19 pandemic and subsequent quarantine. This presentation reviews the implications for the use of long-acting injectable antipsychotics (LAIs) in patients with schizophrenia to manage psychotic symptoms, reduce hospitalizations, and maintain adherence during the COVID-19 pandemic. Topics to be discussed include the general landscape of mental health before and during the COVID-19 pandemic, treatment recommendations for schizophrenia, recommendations for the use of long-acting injectable antipsychotics, and the role of the community pharmacist in treating schizophrenia during the pandemic. The goal of the presentation is to provide guidance on how to evaluate the appropriateness of the use of LAIs and their impact on adherence in patients with schizophrenia.
Speaker(s)/Author(s)
|
Deja Finley, Pharm.D. |
Activity Number
0033-0000-20-058-L01-P
Date:
10/28/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 337 and Virtually
